Figure 7
From: Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML
Gedatolisib delays tumor formation in xenograft mice: mice xenografts (five mice in a group) with sorafenib-resistant MOLM-13 (a) or MV4-11 (b) cells, were treated with gedatolisib or vehicle. Tumor volume was measured at different time points. (c–e) Tumor weight was measured after dissecting tumor from the inhibitor or vehicle-treated mice.
